Zurzuvae: Uses, Dosage & Side Effects
The first oral neuroactive steroid approved for the treatment of postpartum depression in adults, taken once daily for 14 days
Zurzuvae (zuranolone) is a prescription oral medication used to treat postpartum depression (PPD) in adults aged 18 years and older. As the first oral neuroactive steroid specifically approved for postpartum depression, Zurzuvae represents a landmark advancement in the treatment of perinatal mood disorders. It works by enhancing the activity of gamma-aminobutyric acid (GABA) at receptors in the brain that are involved in mood regulation. Zurzuvae is taken once daily in the evening with a fat-containing meal for a single 14-day treatment course. Clinical trials have demonstrated that symptoms of postpartum depression can begin to improve as early as day 3 of treatment, offering rapid relief for mothers who are suffering from this debilitating condition.
Quick Facts: Zurzuvae
Key Takeaways
- Zurzuvae (zuranolone) is the first oral medication specifically approved for postpartum depression, offering a significant alternative to intravenous treatments and traditional antidepressants that take weeks to work.
- The treatment consists of a single 14-day course taken once daily in the evening with a fat-containing meal, with symptom improvement typically beginning by day 3 of treatment.
- Zurzuvae works by enhancing GABA-A receptor activity in the brain, addressing the neurosteroid imbalance that is believed to contribute to postpartum depression after the dramatic drop in allopregnanolone levels following childbirth.
- Do not drive or perform dangerous activities for at least 12 hours after each dose, as Zurzuvae can cause drowsiness, dizziness, and impaired consciousness. Avoid alcohol and grapefruit juice during treatment.
- Zurzuvae must not be taken during pregnancy as it may harm the unborn baby. Use reliable contraception during treatment and for 7 days after the last dose. Breastfeeding should be discussed with your doctor.
What Is Zurzuvae and What Is It Used For?
Zurzuvae contains the active substance zuranolone, a synthetic neuroactive steroid that acts as a positive allosteric modulator (PAM) of gamma-aminobutyric acid type A (GABA-A) receptors. GABA is the primary inhibitory neurotransmitter in the central nervous system and plays a critical role in regulating neuronal excitability, mood, anxiety, and stress responses. By enhancing the activity of GABA at both synaptic and extrasynaptic GABA-A receptors, Zurzuvae helps restore the balance of inhibitory signaling in brain circuits that are disrupted in postpartum depression.
Postpartum depression is a serious mood disorder that affects approximately 10 to 20 percent of women during pregnancy or in the weeks and months following childbirth. It is distinct from the transient “baby blues” that many new mothers experience in the first few days after delivery. Postpartum depression involves persistent and severe symptoms that can significantly interfere with a mother’s ability to care for herself and her infant. These symptoms include persistent sadness or low mood, sleep disturbances beyond those caused by newborn care, significant changes in appetite or weight, difficulty concentrating, feelings of worthlessness or excessive guilt, loss of interest in previously enjoyed activities, psychomotor retardation or agitation, and in severe cases, thoughts of self-harm or harming the infant.
The pathophysiology of postpartum depression is believed to involve a complex interplay of hormonal, neurobiological, psychological, and social factors. One of the leading neurobiological theories centers on the dramatic decline in allopregnanolone levels following childbirth. Allopregnanolone is an endogenous neurosteroid that is a potent positive allosteric modulator of GABA-A receptors. During pregnancy, allopregnanolone levels rise dramatically, increasing approximately 20-fold by the third trimester. After delivery, these levels plummet rapidly. In women who are vulnerable to postpartum depression, this sudden withdrawal of neurosteroid-mediated GABAergic tone is thought to trigger depressive symptoms. Zuranolone, as a synthetic analogue that modulates the same receptors, is designed to compensate for this deficit and restore appropriate GABAergic signaling.
Zurzuvae was evaluated in several pivotal clinical trials. The ROBIN study (a phase III, randomized, double-blind, placebo-controlled trial) enrolled women with severe postpartum depression and demonstrated that zuranolone 30 mg taken for 14 days produced statistically significant improvement in the Hamilton Rating Scale for Depression (HAM-D) score compared with placebo at day 15. The SKYLARK study further confirmed these findings, showing significant improvement in depressive symptoms as early as day 3 of treatment. In both studies, the improvements were sustained through the day 45 follow-up visit, even though treatment lasted only 14 days.
Zurzuvae was first approved by the U.S. Food and Drug Administration (FDA) in August 2023, making it the first oral medication specifically indicated for postpartum depression. The European Medicines Agency (EMA) subsequently approved it for the European market. Prior to the approval of Zurzuvae, the only treatment specifically approved for postpartum depression was brexanolone (Zulresso), which required a 60-hour continuous intravenous infusion administered in a certified healthcare facility. Zurzuvae’s oral formulation and 14-day at-home treatment course represent a significant improvement in convenience and accessibility for patients with postpartum depression.
Zurzuvae enhances the activity of GABA at GABA-A receptors in the brain. GABA is involved in regulating mood, and deficiencies in GABAergic signaling are linked to depression. By acting at both synaptic receptors (which mediate fast, phasic inhibition) and extrasynaptic receptors (which mediate sustained, tonic inhibition), zuranolone provides a comprehensive restoration of inhibitory tone in mood-regulating neural circuits. This dual mechanism of action distinguishes it from benzodiazepines, which primarily act at synaptic receptors only.
What Should You Know Before Taking Zurzuvae?
Contraindications
Zurzuvae must not be taken if you are allergic (hypersensitive) to zuranolone or to any of the other ingredients in the capsules. The inactive ingredients include croscarmellose sodium, mannitol, microcrystalline cellulose, colloidal anhydrous silicon dioxide, and sodium stearyl fumarate. The capsule shell contains gelatin, red iron oxide, titanium dioxide, and yellow iron oxide.
Zurzuvae is strictly contraindicated during pregnancy because it may harm the developing fetus. Animal reproductive studies have shown adverse developmental effects at clinically relevant doses. If you discover that you are pregnant while taking Zurzuvae, stop the medication immediately and contact your healthcare provider. You should use effective contraception during treatment with Zurzuvae and for at least 7 days after your last dose.
Zurzuvae can cause harm to an unborn baby. Do not take Zurzuvae if you are pregnant. Use reliable contraception during treatment and for 7 days after the last dose. If you become pregnant or think you may be pregnant while taking Zurzuvae, contact your doctor immediately.
Warnings and Precautions
Zurzuvae can cause significant central nervous system (CNS) depression, including reduced consciousness and alertness. It is essential that you discuss these potential effects with your healthcare provider before starting treatment. The following warnings are particularly important:
- Driving restriction: Do not drive for at least 12 hours after taking each dose of Zurzuvae. You may not be able to accurately assess how much the medication affects you, and driving under its influence could be extremely dangerous.
- CNS depression: Zurzuvae can cause drowsiness, slow thinking, memory difficulties, confusion, and dizziness during the day. These effects can impair your daily activities, including caring for your child. Do not perform potentially dangerous activities if you experience any of these symptoms.
- Substance abuse history: Tell your doctor if you have a history of alcohol, drug, or prescription medication misuse or dependence, as zuranolone acts on GABA-A receptors in a manner similar to other CNS depressants.
- Mood changes and suicidality: Inform your doctor if you have a history of depression, mood swings, suicidal thoughts, or suicidal behavior. All patients starting treatment for depression should be monitored for clinical worsening and emergence of suicidal ideation, particularly during the initial weeks of treatment.
- Concurrent medications: Ask your doctor whether any other medications you are currently taking could interact with Zurzuvae or prevent you from taking it safely.
Children and Adolescents
Zurzuvae is not intended for use in children and adolescents under 18 years of age. The safety and efficacy of zuranolone have not been studied in this age group. Since postpartum depression is a condition that occurs in the postpartum period, pediatric use is not applicable to the approved indication.
Pregnancy and Breastfeeding
As noted above, Zurzuvae is contraindicated during pregnancy due to the potential risk of harm to the developing fetus. Zurzuvae is specifically designed to be taken after delivery, not during pregnancy. If you are planning to become pregnant, discuss alternative treatment options with your healthcare provider.
Zurzuvae passes into breast milk. The effects of zuranolone on a breastfed infant are not fully known. You should not breastfeed while taking Zurzuvae unless your doctor has specifically advised that it is safe to do so. If you are breastfeeding or planning to breastfeed, talk to your doctor immediately. Together, you can decide on the best approach, which may include temporarily using formula or previously expressed breast milk during the 14-day treatment course and discussing when it is safe to resume breastfeeding after completing treatment.
Driving and Operating Machinery
Do not drive a vehicle or operate heavy machinery for at least 12 hours after taking each dose of Zurzuvae. The medication can cause somnolence (excessive sleepiness), dizziness, confusion, and impaired consciousness that could make driving or operating machinery dangerous. These effects may persist for several hours after each dose. You may not be able to accurately judge how impaired you are while taking Zurzuvae. This restriction applies throughout the entire 14-day treatment course.
Important Information About Ingredients
Zurzuvae contains less than 1 mmol (23 mg) of sodium per dose, meaning it is essentially sodium-free. This is relevant for patients on a sodium-restricted diet. If you have any known intolerances or allergies to the excipients listed above, inform your healthcare provider before starting treatment.
How Does Zurzuvae Interact with Other Drugs?
Zuranolone is primarily metabolized by the cytochrome P450 enzyme CYP3A4 in the liver. This means that other medications or substances that affect CYP3A4 activity can significantly alter the blood levels of zuranolone, potentially leading to increased side effects or reduced effectiveness. It is essential that you inform your doctor or pharmacist about all medications you are taking, have recently taken, or might take, including prescription drugs, over-the-counter medicines, and herbal supplements.
Major Interactions
| Drug Category | Examples | Clinical Impact |
|---|---|---|
| Antifungals | Ketoconazole, posaconazole, voriconazole, itraconazole | Significantly increases zuranolone blood levels; dose adjustment required |
| Antibiotics | Clarithromycin, telithromycin, troleandomycin | Increases zuranolone blood levels; dose adjustment may be needed |
| HIV Antivirals | Ritonavir, lopinavir, indinavir, saquinavir | Strong inhibition of CYP3A4; dose reduction required |
| Cancer Therapies | Ceritinib, idelalisib, ribociclib, tucatinib | Increases zuranolone exposure; consult oncologist and psychiatrist |
When any of the above strong CYP3A4 inhibitors are co-administered with Zurzuvae, your doctor may need to reduce the dose of Zurzuvae to prevent excessive blood levels and an increased risk of side effects such as excessive drowsiness, dizziness, and confusion.
CNS Depressant Interactions
Zurzuvae enhances GABAergic activity in the brain, and combining it with other medications that affect the central nervous system can result in additive or synergistic CNS depression. This can manifest as excessive drowsiness, profound sedation, respiratory depression (in severe cases), and impaired cognitive and motor function. The following drug classes require particular caution:
- Opioid analgesics: Methadone, tramadol, morphine, oxycodone, codeine. Concomitant use may result in profound sedation and should be closely monitored.
- Benzodiazepines and sleep aids: Diazepam, lorazepam, zolpidem, zopiclone. These medications act on the same GABA-A receptors and can significantly amplify the sedating effects of Zurzuvae.
- Sedating antidepressants: Amitriptyline, mirtazapine, trazodone, doxepin, trimipramine. The combined sedative effects may be particularly pronounced.
- Anticonvulsants: Gabapentin and pregabalin. These medications can increase drowsiness and dizziness when combined with Zurzuvae.
Drugs That Reduce Zurzuvae Effectiveness
| Drug | Used For | Clinical Impact |
|---|---|---|
| Rifampin | Antibiotic (tuberculosis) | Substantially reduces zuranolone blood levels; may render treatment ineffective |
| St. John’s Wort | Herbal remedy for mild depression | Reduces zuranolone blood levels; avoid concomitant use |
| Phenobarbital | Epilepsy, sleep disorders | Induces CYP3A4; decreases zuranolone exposure |
| Efavirenz | HIV infection | Moderate CYP3A4 induction; may reduce efficacy |
| Carbamazepine, Phenytoin, Primidone | Epilepsy, seizure disorders | Strong CYP3A4 induction; significantly reduces zuranolone levels |
Food and Alcohol Interactions
Alcohol: Do not consume alcohol or products containing alcohol while taking Zurzuvae without consulting your doctor. Alcohol can significantly worsen the side effects of Zurzuvae, including excessive drowsiness and sedation. The combination of zuranolone and alcohol can result in dangerous levels of CNS depression.
Grapefruit and grapefruit juice: Avoid grapefruit and grapefruit juice during treatment with Zurzuvae. Grapefruit inhibits CYP3A4 in the gut and liver, which can increase the blood levels of zuranolone and lead to enhanced side effects.
Fat-containing food: Zurzuvae should be taken with food that contains fat to optimize absorption. This is not an interaction to avoid, but rather a requirement for the medication to work effectively. Suitable fat-containing foods include cheese, whole milk products, meat, oily fish, avocado, hummus, nuts, peanut butter, chocolate, or nutrition bars containing fat.
What Is the Correct Dosage of Zurzuvae?
Always take Zurzuvae exactly as your doctor or pharmacist has instructed. Zurzuvae is prescribed as a single 14-day treatment course only. Do not stop taking Zurzuvae before completing the full 14-day course, even if you begin to feel better. Symptoms typically start improving by the third day of treatment, but the full treatment course is necessary for optimal benefit.
Adults (Standard Dosing)
Standard Dose
The recommended dose is 50 mg (two 25 mg capsules) taken once daily in the evening with a fat-containing meal for 14 days. Zurzuvae is prescribed as a single treatment course only.
Reduced Dose for Side Effects
If you experience troublesome side effects, your doctor may reduce the dose to 40 mg (two 20 mg capsules) taken once daily in the evening.
Dose with CYP3A4 Inhibitors
If you are taking a strong CYP3A4 inhibitor concurrently, your doctor may reduce the Zurzuvae dose to prevent increased blood levels and side effects.
Kidney and Liver Impairment
Moderate to Severe Kidney Problems or Severe Liver Problems
Patients with moderate to severe renal impairment or severe hepatic impairment should take a reduced dose of 30 mg (one 30 mg capsule) once daily in the evening for 14 days.
How to Take Zurzuvae Capsules
Follow these instructions carefully to ensure you get the maximum benefit from your treatment:
- Swallow the capsules whole without chewing or opening them.
- Take Zurzuvae with a fat-containing meal to increase absorption and ensure effective treatment. Suitable fat-containing foods include: cheese, whole milk products and yogurt; meat, oily fish; avocado, hummus, soy products (tofu); nuts, peanut butter, chocolate, or fat-containing nutrition bars or drinks. These can be taken as a meal or a snack.
- Take your dose in the evening to minimize the impact of daytime drowsiness.
- Take every day for 14 days without interruption for optimal results.
Missed Dose
If you forget to take Zurzuvae, skip the missed dose and take your next dose at your usual time the following evening. Do not take a double dose to make up for a missed dose. Continue taking Zurzuvae once daily until you have completed the full treatment course as prescribed by your doctor.
Overdose
If you have taken more Zurzuvae than prescribed, seek immediate medical attention by calling your doctor or going to the nearest emergency department. Do not drive yourself, as you may become very drowsy. Always bring the medication packaging with you to show the doctor, even if there are no capsules remaining. Symptoms of overdose may include excessive drowsiness, profound sedation, confusion, and difficulty staying awake.
Stopping Treatment
Zurzuvae treatment can be stopped after the 14-day course without the need to gradually reduce the dose (no tapering required). The medication is designed as a short-course treatment, and abrupt discontinuation after completing the full course is not associated with withdrawal symptoms.
What Are the Side Effects of Zurzuvae?
Like all medications, Zurzuvae can cause side effects, although not everyone will experience them. The side effects listed below are based on data from clinical trials and post-marketing reports. Because Zurzuvae acts on GABA-A receptors in the brain, the most commonly reported side effects are related to CNS depression, including drowsiness, dizziness, and cognitive impairment.
If you experience any of the following side effects, contact your healthcare provider. Most side effects are mild to moderate in severity and tend to resolve within the 14-day treatment period or shortly after treatment is completed. However, if any side effect becomes severe or does not improve, seek medical advice promptly.
Very Common
May affect more than 1 in 10 people
- Drowsiness or excessive sleepiness (somnolence)
- Dizziness
Common
May affect up to 1 in 10 people
- Diarrhea (loose stools)
- Fatigue (feeling tired or lacking energy)
- Difficulty remembering information (memory impairment)
- Tremor (shaking or trembling)
- Confusion (feeling confused or disoriented)
The most frequently reported side effects, somnolence and dizziness, are consistent with the pharmacological mechanism of action of zuranolone as a GABA-A receptor modulator. These effects are typically most pronounced in the first few days of treatment and may diminish as treatment continues. Taking Zurzuvae in the evening as directed helps to minimize the impact of drowsiness on daytime activities.
Contact your healthcare provider immediately if you experience: severe confusion or disorientation that prevents you from caring for yourself or your baby; excessive sedation where you have difficulty staying awake; severe dizziness that affects your balance and increases fall risk; any signs of allergic reaction such as rash, swelling, or difficulty breathing; or any worsening of depressive symptoms or emergence of suicidal thoughts.
It is important to understand that the side effects of Zurzuvae must be weighed against the significant burden of untreated postpartum depression. Postpartum depression, if left untreated, can have profound negative effects on maternal health, the mother-infant bond, infant development, and family relationships. The 14-day treatment duration means that any side effects experienced with Zurzuvae are time-limited, and most resolve after the treatment course is completed.
It is important to report any suspected side effects to your healthcare provider or to your national pharmacovigilance authority. Reporting helps to continuously monitor the benefit-risk balance of the medication and contributes to the ongoing safety evaluation of Zurzuvae.
How Should You Store Zurzuvae?
Proper storage of medications is essential to maintain their effectiveness and safety. Follow these storage guidelines carefully for Zurzuvae:
- Temperature: Store below 25°C (77°F). Do not refrigerate or freeze.
- Children: Keep Zurzuvae out of the sight and reach of children at all times. This is especially important in a household with a newborn, as the medication may be stored in areas accessible to older children.
- Expiration date: Do not use Zurzuvae after the expiration date (EXP) stated on the bottle or blister pack. The expiration date refers to the last day of the indicated month.
- Disposal: Do not throw unused medications in the toilet or household waste. Ask your pharmacist how to properly dispose of medications you no longer need. These measures help protect the environment.
What Does Zurzuvae Contain?
Understanding the composition of your medication can help you identify potential allergens and understand what you are taking. Each Zurzuvae capsule contains the following:
Active Ingredient
| Capsule Strength | Zuranolone Content | Appearance |
|---|---|---|
| Zurzuvae 20 mg | 20 mg zuranolone | Light orange cap, off-white to pale yellow body, printed “S-217 20mg” in black |
| Zurzuvae 25 mg | 25 mg zuranolone | Light orange cap and body, printed “S-217 25mg” in black |
| Zurzuvae 30 mg | 30 mg zuranolone | Orange cap, light orange body, printed “S-217 30mg” in black |
Inactive Ingredients
- Capsule contents: Croscarmellose sodium (E 468), mannitol (E 421), microcrystalline cellulose (E 460), colloidal anhydrous silicon dioxide (E 551), sodium stearyl fumarate
- Capsule shell: Gelatin (E 441), red iron oxide (E 172), titanium dioxide (E 171), yellow iron oxide (E 172)
- Capsule printing ink: Ammonium hydroxide (E 527), black iron oxide (E 172), propylene glycol (E 1520), shellac glaze (E 904)
Pack Sizes
Zurzuvae is available in the following pack sizes:
- Bottles: 14 or 28 capsules (20 mg or 25 mg); 14 capsules (30 mg)
- Blister packs: 28 capsules (20 mg or 25 mg)
Not all pack sizes may be marketed in every country.
Frequently Asked Questions About Zurzuvae
Zurzuvae (zuranolone) differs from traditional antidepressants in several important ways. First, it works through a different mechanism: while traditional antidepressants like SSRIs (selective serotonin reuptake inhibitors) and SNRIs primarily target serotonin and norepinephrine systems, Zurzuvae enhances GABA-A receptor activity. Second, Zurzuvae works much faster, with symptom improvement beginning as early as day 3, compared to the 4-6 weeks typically required for traditional antidepressants. Third, Zurzuvae is taken for only 14 days as a single treatment course, whereas traditional antidepressants are usually taken for months or years. Finally, Zurzuvae is specifically approved for postpartum depression, while traditional antidepressants are used for various types of depression.
In clinical trials, the improvement in depressive symptoms achieved during the 14-day treatment course with Zurzuvae was sustained through day 45 (approximately 4 weeks after completing treatment). This sustained benefit, despite the short treatment duration, is believed to be related to the way zuranolone helps reset the brain’s GABAergic signaling, which may have a lasting impact on the neural circuits involved in mood regulation. However, if your symptoms return or worsen after completing the treatment course, contact your healthcare provider to discuss additional treatment options.
This depends on the specific antidepressant you are taking. In some clinical trials, patients were allowed to continue their existing antidepressant while taking Zurzuvae. However, sedating antidepressants (such as amitriptyline, mirtazapine, or trazodone) may worsen the drowsiness and dizziness caused by Zurzuvae. You should never start, stop, or change any medication without first consulting your doctor. Your healthcare provider will assess whether your current antidepressant can be safely combined with Zurzuvae and may adjust dosages if necessary.
Zuranolone is a lipophilic (fat-soluble) molecule, meaning it dissolves in fat rather than water. When taken with a fat-containing meal, the fats in the food help increase the absorption of zuranolone from the gastrointestinal tract into the bloodstream. This significantly increases the bioavailability of the drug, meaning more of the active ingredient reaches its target in the brain. Without adequate fat in the meal, zuranolone absorption is substantially reduced, and the medication may not reach therapeutic levels needed to effectively treat postpartum depression. This is why it is important to always take Zurzuvae with food containing fat, even if it is just a small snack like nuts, cheese, or peanut butter.
Zurzuvae can cause drowsiness, dizziness, confusion, and impaired consciousness, which may affect your ability to safely care for your baby. It is important to have support from a partner, family member, or caregiver during the 14-day treatment course, especially during the hours when the medication’s sedating effects are strongest (typically the first few hours after taking the evening dose). Plan ahead before starting treatment: arrange for someone who can assist with nighttime feedings and other baby care tasks. If you feel that the medication is significantly impairing your ability to function during the day, contact your doctor. The benefits of treating postpartum depression generally outweigh the temporary limitations on certain activities, as untreated PPD itself significantly impairs maternal caregiving ability.
Zurzuvae is currently approved as a single 14-day treatment course. If your symptoms return after completing treatment, contact your healthcare provider. They will assess your condition and may recommend additional treatment options, which could include a different antidepressant, psychotherapy, or other interventions. The decision about whether a second course of Zurzuvae is appropriate would be made by your doctor based on your individual circumstances and the most current prescribing guidance.
References
- European Medicines Agency (EMA). Zurzuvae (zuranolone) – Summary of Product Characteristics. 2025. Available at: www.ema.europa.eu
- U.S. Food and Drug Administration (FDA). Zurzuvae (zuranolone) Prescribing Information. August 2023. Available at: www.fda.gov
- Deligiannidis KM, Meltzer-Brody S, Gunduz-Bruce H, et al. Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial (ROBIN Study). JAMA Psychiatry. 2021;78(9):951-959. doi:10.1001/jamapsychiatry.2021.1559
- Deligiannidis KM, Citrome L, Gunduz-Bruce H, et al. Zuranolone for the Treatment of Postpartum Depression (SKYLARK Study). American Journal of Psychiatry. 2023;180(9):668-675.
- World Health Organization (WHO). Guide for Integration of Perinatal Mental Health in Maternal and Child Health Services. 2022. Available at: www.who.int
- American Psychiatric Association (APA). Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts. 2023.
- National Institute for Health and Care Excellence (NICE). Antenatal and Postnatal Mental Health: Clinical Management and Service Guidance (CG192). Updated 2023.
- Meltzer-Brody S, Kanes SJ. Allopregnanolone in postpartum depression: Role in pathophysiology and treatment. Neurobiology of Stress. 2020;12:100212. doi:10.1016/j.ynstr.2020.100212
Editorial Team
This article was prepared and reviewed by the iMedic Medical Editorial Team, comprising specialists in psychiatry, clinical pharmacology, and perinatal mental health.
Medical Content
iMedic Medical Editorial Team – Specialists in Psychiatry and Clinical Pharmacology
Medical Review
iMedic Medical Review Board – Independent Expert Panel
Evidence Assessment
GRADE Framework – Level 1A (Systematic Reviews and RCTs)
Quality Assurance
WHO, EMA, FDA, APA, and NICE guideline compliance verified
All content on iMedic is prepared independently without pharmaceutical company sponsorship or commercial funding. Our editorial team follows the GRADE evidence framework and adheres to international medical guidelines. For more information about our editorial standards, visit our Editorial Standards page.